Leerink Partnrs Has Bullish Forecast for JANX Q2 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Analysts at Leerink Partnrs boosted their Q2 2025 earnings per share estimates for Janux Therapeutics in a research report issued on Monday, May 12th. Leerink Partnrs analyst J. La. Rosa now expects that the company will post earnings of ($0.47) per share for the quarter, up from their previous forecast of ($0.49). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share. Leerink Partnrs also issued estimates for Janux Therapeutics’ Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at ($4.76) EPS, FY2027 earnings at ($5.42) EPS, FY2028 earnings at ($4.20) EPS and FY2029 earnings at ($2.01) EPS.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%.

A number of other research analysts have also recently commented on JANX. Wedbush reaffirmed an “outperform” rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Scotiabank dropped their price objective on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Janux Therapeutics presently has an average rating of “Buy” and a consensus target price of $95.25.

Janux Therapeutics Stock Performance

JANX opened at $23.27 on Wednesday. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -19.89 and a beta of 3.24. The stock’s 50 day moving average price is $28.76 and its 200-day moving average price is $40.94. Janux Therapeutics has a one year low of $22.48 and a one year high of $71.71.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the company’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the transaction, the insider now owns 82,139 shares in the company, valued at $2,630,912.17. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now directly owns 9,658,988 shares of the company’s stock, valued at approximately $295,951,392.32. This trade represents a 3.67% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 10,001 shares of company stock worth $313,964 over the last 90 days. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. lifted its holdings in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after acquiring an additional 442 shares during the period. Avanza Fonder AB lifted its holdings in shares of Janux Therapeutics by 17.0% during the 1st quarter. Avanza Fonder AB now owns 3,049 shares of the company’s stock worth $86,000 after acquiring an additional 444 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Janux Therapeutics by 3.0% during the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company’s stock worth $444,000 after acquiring an additional 471 shares during the period. Rhumbline Advisers lifted its holdings in shares of Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after acquiring an additional 599 shares during the period. Finally, Exchange Traded Concepts LLC increased its position in shares of Janux Therapeutics by 20.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company’s stock worth $109,000 after purchasing an additional 686 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.